Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Psychological Impact of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation on Donors

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Allogeneic hematopoietic stem cell transplantation (allo-HSC) is currently one of the only curative treatments for haematological malignancies with a poor prognosis, the realization of which presupposes the identification and availability of a compatible donor. In recent years, haploidentical transplants have been developed, a reliable alternative for patients who do not have 100% compatible donors. The development of haplo-identical transplants leads to an exponential increase in the use of intra-family donation. Intrafamilial donation of hematopoietic stem cells (HSC) has the advantages of lower financial cost and faster availability of the graft, thus avoiding the risk of relapse before the procedure. Nevertheless, intrafamilial donation raises clinical and ethical questions. Indeed, the psychological impact of intra-family donation on the donor cannot be overlooked. Thus, in the context of the development of haplo-identical transplants, measuring the impact of donation on donors (ascendants and descendants) will make it possible to assess the relevance of taking psychosocial aspects into consideration in the choice of donors, to assess the psychological impact of haplo-identical donation and to offer psychological support adapted to donors.

Who May Be Eligible (Plain English)

Who May Qualify: - Identical haplo CSH donors ascending (parents) or descending (children) - Major identical haplo HSC donors - Haplo-identical HSC donors living in mainland France and cared for in the centers participating in the study - Haplo-identical HSC donors benefiting from Social Security System. - Haplo-identical HSC donors who have signed the consent form - \- Ability to read and write in French Who Should NOT Join This Trial: \- Insufficient understanding of the French language Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * Identical haplo CSH donors ascending (parents) or descending (children) * Major identical haplo HSC donors * Haplo-identical HSC donors living in mainland France and cared for in the centers participating in the study * Haplo-identical HSC donors benefiting from Social Security System. * Haplo-identical HSC donors who have signed the consent form * \- Ability to read and write in French Exclusion Criteria: \- Insufficient understanding of the French language

Treatments Being Tested

OTHER

Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.

Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant

Locations (1)

Service D'hématologie Clinique et thérapie cellulaire - Hôpital St Antoine
Paris, France